Post-Interleukin 1
| PHA Biologicals |
32313848 ä. Precision medicine in COVID-19: IL-1 beta a potential target
32376597 2020. Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series
32228825 2020. How to reduce the likelihood of coronavirus-19 (CoV-19 or SARS-CoV-2) infection and lung inflammation mediated by IL-1
32373790 2020. Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome
32482538 ä. Propuesta de uso de anakinra en el distres respiratorio agudo secundario a COVID-19
32456767 2020. Anakinra in COVID-19 therapy: what have we learned from adult-onset Still's disease?
32438450 2020. Interleukin-1 blockade with anakinra in acute leukaemia patients with severe COVID-19 pneumonia appears safe and may result in clinical improvement.
32437739 2020. Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease.
32462848 2020. Interleukine-1 et blocage du COVID-19.
32422376 2020. Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe Coronavirus disease 2019: A case report.
32437934 2020. Use of anakinra in severe COVID-19: a case report.
32501454 2020. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study.
32487869 2020. COVID-19 and myocardial injury: is there a role for interleukin-1 inhibition?
32583087 2020. IL-1R blockade is not effective in patients with hematological malignancies and severe SARS-CoV-2 infection.
32568376 2020. Successful treatment of severe COVID-19 with subcutaneous anakinra as a sole treatment.
32411313 2020. FAVORABLE ANAKINRA RESPONSES IN SEVERE COVID-19 PATIENTS WITH SECONDARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS.
32571730 2020. Anakinra, una alternativa potencial en el tratamiento de la infeccion respiratoria grave por SARS-CoV-2 refractaria a tocilizumab.
32602262 2020. Use of Anakinra to Prevent Mechanical Ventilation in Severe COVID-19: A Case Series.
32734502 2020. Anakinra for the Treatment of COVID-19-Associated Pericarditis: A Case Report.
32768693 2020. Early identification of COVID-19 cytokine storm and treatment with anakinra or tocilizumab.
32838316 2020. Effect of anakinra in COVID-19.
32838317 2020. Effect of anakinra in COVID-19 - Authors' reply.
32838318 2020. Anakinra for severe forms of COVID-19.
32838319 2020. Anakinra for severe forms of COVID-19.
32838320 2020. Anakinra for severe forms of COVID-19.
32838321 2020. Anakinra for severe forms of COVID-19 - Authors' reply.
32843231 2020. High dose subcutaneous Anakinra to treat acute respiratory distress syndrome secondary to cytokine storm syndrome among severely ill COVID-19 patients.
32860431 2020. Evaluation of seventeen patients with COVID-19 pneumonia treated with anakinra according to HScore, SOFA, MuLBSTA and Brescia-COVID respiratory severity scale (BCRSS) scoring systems.
32914670 2020. Biomarker-guided application of low-dose anakinra in an acute respiratory distress syndrome patient with severe COVID-19 and cytokine release syndrome.
32933914 2020. Cytokine storm and use of anakinra in a patient with COVID-19.
32951346 2020. Reply - "Anakinra for COVID-19: how to interpret elevations in liver enzymes".
32959495 2020. Anakinra for COVID-19: how to interpret elevations in serum liver enzymes.
32964179 2020. Safety of intravenous anakinra in COVID-19 with evidence of hyperinflammation, a case series.
33010355 2020. Jaundice in a patient treated with Anakinra in a context of Covid-19.
33023646 2020. Anakinra: a silver lining in COVID-19?
33073222 2020. Rapid Response to Cytokine Storm Inhibition using Anakinra in a Patient with COVID-19 Myocarditis.
33217576 2020. Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy: results of a prospective, open-label, interventional study.
33220354 2020. Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: an observational cohort study.
33302991 2020. Anakinra treatment in critically ill COVID-19 patients: a prospective cohort study.
C7241987 2020. Anakinra in COVID-19: important considerations for clinical trials.
C7259909 2020. Anakinra for severe forms of COVID-19: a cohort study.
C7316444 2020. Anakinra for patients with COVID-19 ? Authors reply.
C7316448 2020. Anakinra for patients with COVID-19.
C7316458 2020. Anakinra for patients with COVID-19.
C7316462 2020. Anakinra for patients with COVID-19.
C7648207 2020. Adalimumab/anakinra/dexamethasone: COVID-19 infection cytomegalovirus reactivation and off-label use: case report.
32682440 2020. Blocking IL-1 to prevent respiratory failure in COVID-19.
32699149 2020. Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19.
32737105 2020. Targeting IL-1, IL-6 or GM-CSF in COVID-19. Response to: 'More evidences on which biologic and which pathway is key in severe-critical COVID-19 pneumonia' by Ferraccioli.
32744052 2020. IL-1 induces throboxane-A2 (TxA2) in COVID-19 causing inflammation and micro-thrombi: inhibitory effect of the IL-1 receptor antagonist (IL-1Ra).
